Legal challenges to FDA regulations -- specifically the agency's ban on off-label promotion -- are emerging in the wake of the U.S. Supreme Court decision in Sorrell v. IMS Health. Read more about the recent legal actions, and how they may redefine off-label promotional activities, in an article posted on the Coalition for Healthcare Communication website, courtesy of The RPM Report.

Full Story:

Related Summaries